PMID- 19626818
OWN - NLM
STAT- MEDLINE
DCOM- 20090814
LR  - 20131121
IS  - 0125-2208 (Print)
IS  - 0125-2208 (Linking)
VI  - 92
IP  - 7
DP  - 2009 Jul
TI  - Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once 
      daily in patients with lower urinary tract symptoms suggestive of benign 
      prostatic hyperplasia.
PG  - 969-78
AB  - OBJECTIVE: Assess safety and efficacy of 10-mg prolonged-release alfuzosin 
      (Xatral XL) in benign prostatic hyperplasia (BPH) patients with lower urinary 
      tract symptoms (LUTS). MATERIAL AND METHOD: A multicenter observational study 
      looking at safety by adverse events (AEs) incidence, efficacy by changes in 
      International Prostate Symptom Score (I-PSS), quality of life index (QOL), sexual 
      function using Danish Prostate Symptom Score (DAN-PSS sex), and flow rates. 
      Patients were allocated to receive alfuzosin (Xatral XL) 10 mg once daily tablet 
      along with a meal for 6 months. Patients were assessed at 3 months and 6 months. 
      RESULTS: In 118 males, 22% had AEs (most common was dizziness). Ten patients 
      discontinued the treatment. Of those patients, five had serious AEs, which only 
      one was related to the study. At month 6, there were improvements from baseline 
      in mean I-PSS (-9.3, p < 0.001), in QOL index (-2.96, p < 0.001), in symptom 
      (-0.72, p < 0.05) and bothersome (-1.13, p < 0.01) subscores on DAN-PSS sex, and 
      in mean flow rate (0.92, p < 0.01). Approximately 74% patients improved within 
      two weeks. There was one case of Acute urinary retention (AUR), which none 
      required surgery. CONCLUSION: A 10-mg prolonged-release alfuzosin safely and 
      rapidly relieves LUTS and maintains improvement. It also improves BPH-associated 
      sexual dysfunction.
FAU - Kongkanand, Apichat
AU  - Kongkanand A
AD  - King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.
FAU - Chodchoy, Viroj
AU  - Chodchoy V
FAU - Lojanapiwat, Bannakij
AU  - Lojanapiwat B
FAU - Pumpaisanchai, Somkiat
AU  - Pumpaisanchai S
FAU - Ratana-Olarn, Krisada
AU  - Ratana-Olarn K
FAU - Sae-Tang, Pat
AU  - Sae-Tang P
FAU - Taweemonkongsap, Tawatchai
AU  - Taweemonkongsap T
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - J Med Assoc Thai
JT  - Journal of the Medical Association of Thailand = Chotmaihet thangphaet
JID - 7507216
RN  - 0 (Adrenergic alpha-Antagonists)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Quinazolines)
RN  - 90347YTW5F (alfuzosin)
SB  - IM
MH  - Adrenergic alpha-Antagonists/*administration & dosage
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Delayed-Action Preparations
MH  - Ejaculation/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Penile Erection/drug effects
MH  - Prostatic Hyperplasia/complications/diagnosis
MH  - Quinazolines/*administration & dosage
MH  - Urinary Retention/*drug therapy/etiology/prevention & control
EDAT- 2009/07/25 09:00
MHDA- 2009/08/15 09:00
CRDT- 2009/07/25 09:00
PHST- 2009/07/25 09:00 [entrez]
PHST- 2009/07/25 09:00 [pubmed]
PHST- 2009/08/15 09:00 [medline]
PST - ppublish
SO  - J Med Assoc Thai. 2009 Jul;92(7):969-78.